Project 3: Immune Markers Linking Pathogenesis in Animal Models and Human Neurodegenerative Disease

Information

  • Research Project
  • 9747921
  • ApplicationId
    9747921
  • Core Project Number
    P20GM109025
  • Full Project Number
    5P20GM109025-05
  • Serial Number
    109025
  • FOA Number
    PAR-14-035
  • Sub Project Id
    5775
  • Project Start Date
    -
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    6/1/2019 - 5 years ago
  • Budget End Date
    5/31/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    05
  • Suffix
  • Award Notice Date
    6/7/2019 - 5 years ago

Project 3: Immune Markers Linking Pathogenesis in Animal Models and Human Neurodegenerative Disease

Project Summary/Abstract Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive loss of memory. Pathological hallmarks of AD include amyloid-beta (A?) plaque deposition, neurofibrillary tangle (NFT) formation and the progressive loss of synapses and neurons. A growing literature has indicated that immune activation in the brain, in particular activated microglia may contribute to the progression of AD by facilitating A? deposition and NFTs. These findings fit well with the identification of several risk factors in AD are associated with immune and inflammatory pathways. Separate data indicate the endogenous neurotransmitter GABA is capable of modulating activation of microglia and immune function. The identification of mechanisms involved in modulating immune activation in AD may provide valuable insight into disease progression as well as identify novel therapeutic targets. Project 3 will determine the extent to which changes in the GABA transmitter system may be involved in immune activation in AD. We will determine if changes in GABA signaling are related to behavioral impairments and pathological changes in the brain (A?, NFT) in an animal model of AD. We will further evaluate the impact of the loss of a specific GABA receptor on microglia in the AD animal model to determine if the immune response in AD is altered. Lastly, we propose to determine if the loss of a specific GABA receptor on microglia exacerbates behavioral and pathological deficits consistent with AD. These data may provide invaluable information for a mechanism to addresses immune activation and the progression of AD.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    332359
  • Indirect Cost Amount
    0
  • Total Cost
  • Sub Project Total Cost
    332359
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIGMS:332359\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CLEVELAND CLINIC FOUNDATION
  • Organization Department
  • Organization DUNS
    017730458; 809775336
  • Organization City
    CLEVELAND
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    441950001
  • Organization District
    UNITED STATES